Midazolam Mercury Pharmaceuticals (Ireland) (Midazolam)

Midazolam enhances the activity of the inhibitory neurotransmitter GABA by binding to a specific site on the GABA‑A receptor complex. This increases chloride ion influx, hyperpolarising neurons and reducing excitability, which produces sedation, anxiolysis, anticonvulsant effects and muscle relaxation.

The dose of Midazolam is individualized and determined by the prescribing clinician based on the patient’s age, weight, clinical condition and the intended use. Healthcare professionals calculate the appropriate intravenous dose and titrate it to achieve the desired level of sedation or seizure control.

Midazolam is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be used during pregnancy only when the potential benefit justifies the risk. Limited data are available for breastfeeding; caution is advised, and alternatives should be considered when possible.

To order Midazolam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Midazolam is a short‑acting benzodiazepine, offering faster onset and shorter recovery than longer‑acting agents such as diazepam. Compared with propofol, another common sedative, Midazolam provides more pronounced anxiolysis and amnesia but may cause greater respiratory depression when combined with opioids.

Midazolam injectable solution should be stored below 25 °C, protected from light and moisture, and kept in its original vial until use. Once opened, it must be used promptly and any remaining product discarded according to local regulations to maintain sterility.

Midazolam is administered intravenously by a qualified healthcare professional. It can be given as a bolus injection for rapid effect or as a continuous infusion for longer procedures. Dosing is titrated to the desired clinical response while monitoring vital signs.

The most critical risks include severe respiratory depression, profound hypotension, paradoxical reactions such as agitation or seizures, and rare allergic reactions. Continuous monitoring of respiration, blood pressure and level of consciousness is essential, especially when used with other central nervous system depressants.

Midazolam is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are dependent on chronic benzodiazepine therapy without proper tapering. Caution is also required in the elderly, patients with hepatic impairment, and pregnant women.